BATS BZX Real-Time Price
| +0.06 / +0.66%|
The 3 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 12.00, with a high estimate of 15.00 and a low estimate of 11.00. The median estimate represents a +31.29% increase from the last price of 9.14.
The current consensus among 4 polled investment analysts is to Buy stock in ZIOPHARM Oncology Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.